Search Patents
  • Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
    Patent number: 5484885
    Abstract: Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants of monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.
    Type: Grant
    Filed: March 19, 1992
    Date of Patent: January 16, 1996
    Assignee: Emory University
    Inventors: Heloise A. Pereira, John K. Spitznagel
  • Method for production and purification of hepatitis B vaccine
    Patent number: 5242812
    Abstract: Processes are provided for producing purified, hepatitis B surface antigen particles in mammalian cells which comprise culturing mammalian cells which produce the particles in a culture medium supplemented with a serum free of high molecular weight contaminant proteins and recovering the purified, hepatitis B surface antigen particles.Removal of molecules having a molecular weight greater than about 3.times.10.sup.5 daltons by prefractionation, for example, allows cells to be grown in culture media containing high levels of fetal calf serum, removes high molecular weight contaminant proteins which may be inhibitory to cell growth and simplifies purification of HBsAg since high molecular weight contaminant proteins are the major contaminants removed by purification processes.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: September 7, 1993
    Assignee: Bio-Technology General Corp.
    Inventor: Zeev Even-Chen
  • Process for obtaining active proteins from a biologically inactive form
    Patent number: 4965344
    Abstract: A process for the preparation of a spatial form, which has biological activity, of a protein from a biologically inactive spatial form is described and comprises the protein being dissolved with the addition of a denaturing agent and thus converted into the random coil form, and the solution being allowed to pass through a material which has molecular sieve properties and contains a liquid medium in which the protein can assume a spatial form which has biological activity, and this material having molecular sieve properties being selected so that the molecules of the denaturing agent can penetrate, but the protein molecules canot. It is possible by centrifugation, blowing or sucking out to remove the medium in the "external volume" of the molecular sieve and to increase the rate of passage of the solution through the molecular sieve.
    Type: Grant
    Filed: June 2, 1987
    Date of Patent: October 23, 1990
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Reinhard Hermann
  • Lung growth stimulatory and inhibitory factors for carcinoma tumor cells
    Patent number: 5164489
    Abstract: The invention relates to the purification and characterization of growth stimulatory and inhibitory protein factors produced by various organs which appear to play a role in the successful formation of metastatic colonies of tumor cells. In particular, it has been found that syngeneic organs secrete protein growth stimulatory and inhibitory factors which can, at low concentrations, affect metastatic tumor cells. The ability of a malignant cell to respond to these factors is believed to be related to tumor cell metastasis to specific body organs. In particular a lung growth stimulatory glycoprotein having a molecular weight of approximately 66,000 daltons has been found to stimulate growth of lung-metastatic rat and human mammary tumor cells in serum deprived medium.
    Type: Grant
    Filed: May 23, 1988
    Date of Patent: November 17, 1992
    Assignee: Board of Regents, University of Texas System
    Inventors: Garth L. Nicolson, Philip G. Cavanaugh
  • Method of increasing monocyte chemotaxis with CAP37 and monocyte chemotactic portions thereof
    Patent number: 5458874
    Abstract: Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.
    Type: Grant
    Filed: October 30, 1992
    Date of Patent: October 17, 1995
    Assignee: Emory University
    Inventors: Heloise A. Pereira, John K. Spitznagel
  • Synergistic antifungal protein and compositions containing same
    Patent number: 5703044
    Abstract: Novel plant proteins (SAFPs) which synergize the activity of antifungal antibiotics are identified. SAFPs are demonstrated to synergize antifungal antibiotics, such as nikkomycins, polyoxins and amphotericins. SAFPs alone also display antifungal activity against several species of fungi, including strains of Candida, Trichoderma, Neurospora and strains of the plant pathogens Fusarium, Rhizoctonia and Chaetomium. Synergistic antifungal compositions containing SAFP and antifungal antibiotics are provided. In particular, synergistic compositions of corn-SAFP (zeamatin), sorghum-SAFP (sormatin) or oat-SAFP (avematin) and nikkomycin are found to be effective as antifungal compositions, especially against the opportunistic human pathogen Candida albicans. Method for employing SAFPs and synergistic compositions containing them for the inhibition of fungi are provided. In addition, a method for purifying SAFP from grain meal is provided.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 30, 1997
    Assignee: Novartis Finance Corporation
    Inventors: Walden K. Roberts, Claude P. Selitrennikoff, Bridget E. Laue, Sharon L. Potter
  • Therapeutic fibrinogen compositions
    Patent number: 5330974
    Abstract: A therapeutic composition effective on contact with thrombin at a site of treatment in a patient as a tissue adhesive, hemostat or sealant, said composition comprising non-autologous, non-single donor mammalian fibrinogen that is capable of polymerizing when provided in solution at said site at a concentration of about 30 mg/ml thereof or less, to a fibrin network having therapeutically effective strength, wherein said composition contains less than about 30% (w/w), based on total protein mass present therein, of proteins other than fibrinogen, and further comprises a sufficient amount of one or more low molecular weight physiologically-compatible solutes such that said composition, if formulated as a lyophilized material, can be reconstituted therefrom at room temperature in sterile water for injection in about 30 minutes or less, at about 25 mg/ml of said fibrinogen. Additionally, methods for producing and maintaining said composition, and methods for the use thereof.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: July 19, 1994
    Assignee: Fibratek, Inc.
    Inventors: Eli Pines, William J. White
  • Method of isolating restriction fragment deletions in Vibrio cholerae, and products thereof
    Patent number: 5470729
    Abstract: Methods of isolating deletion mutants of Vibrio cholerae. In one method, the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination between a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. In another method, an initial in vivo recombination event of homologous sequences from the recombinant plasmid into the chromosome provides a selectable marker at this site. A second in vivo recombination event between homologous flanking sequences results in excision of proficient genes from the chromosome with the end product being a deletion mutation. Also provided are methods for the isolation and characterization of a new Vibrio cholerae strain having a deletion in the ctx gene, as defined by Acc I, Xba I, Cla I and/or restriction endonuclease sites and further having a deletion in the gene encoding zonula occludens toxin (zot).
    Type: Grant
    Filed: August 12, 1992
    Date of Patent: November 28, 1995
    Assignee: University of Maryland At Baltimore
    Inventors: James B. Kaper, Bernadette Baudry-Maurelli, Alessio Fasano
  • Therapeutic uses of human somatomedin carrier proteins
    Patent number: 5681818
    Abstract: This invention relates to polypeptides that are human somatomedin carrier protein subunits and to processes for producing them. The carrier protein subunits bind to human somatomedin-like polypeptides, also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-1, by a molecule of various chromatographic steps.This invention also relates to DNA molecules encoding human somatomedin carrier protein-like polypeptides, recombinant DNA molecules, hosts, processes for producing carrier protein-like polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human carrier protein or a human carrier protein subunit capable of binding somatomedins.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: October 28, 1997
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Emerald Martin Spencer, Carol Talkington-Verser
  • Separation of anti-metal chelate antibodies
    Patent number: 5112951
    Abstract: The present invention provides a method for the separation of anti-metal chelate antibodies from non-specific proteins, including antibodies, by applying a preparation containing the anti-metal chelate antibodies to an oxo acid derivatized solid support and eluting first with an elution buffer containing sufficient salt concentration to elute non-specific proteins but not sufficient to elute the anti-metal chelate antibodies and then increasing the salt concentration of the elution solution so as to elute the anti-metal chelate antibodies. In one embodiment, the oxo acid derivatized solid support is a sulfopropyl resin. Appropriate salts include sodium phosphate, sodium chloride and sodium acetate. The method can be used to separate monoclonal or polyclonal anti-metal chelate antibodies from non-specific proteins as well as to separate bifunctional anti-metal chelate antibodies from monoclonal anti-metal chelate antibodies and other non-specific proteins.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: May 12, 1992
    Assignee: Hybritech Incorporated
    Inventors: Daniel E. Beidler, Rodney A. Jue
  • MN gene and protein
    Patent number: 5387676
    Abstract: A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and fusion proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins.
    Type: Grant
    Filed: October 21, 1992
    Date of Patent: February 7, 1995
    Assignee: Ciba Corning Diagnostics Corp.
    Inventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
  • Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
    Patent number: 5767072
    Abstract: Disclosed are methods and compositions for the treatment of HIV infections through the specific elimination of cells which express HIV env determinants such as gp120. The compositions of the invention include toxin conjugates composed of a CD4 derived gp120 binding ligand conjugated to a toxin A chain moiety such as ricin A chain or deglycosylated ricin A chain. Where a therapeutic composition is desired, the conjugates are formed by means of a cross linker which includes a disulfide bond. Disulfide linkages are not crucial where non-therapeutic uses, such as antibody generation, is intended. In preferred aspects of the invention, conjugates incorporating shorter CD4 peptides, such as those incorporating amino acids 41-57 or 41-84 of CD4, are disclosed.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: June 16, 1998
    Assignee: Board of Regents, The University of Texas System
    Inventors: Ellen S. Vitetta, Jonathan W. Uhr
  • Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
    Patent number: 5200509
    Abstract: This invention relates to polypeptides that are human somatomedin carrier protein subunits and to processes for producing them. The carrier protein subunits bind to human somatomedin-like polypeptides also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-1, by a molecule of various chromatographic steps.This invention also relates to DNA molecules encoding human somatomedin carrier protein-like polypeptides, recombinant DNA molecules, hosts, processes for producing carrier protein-like polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human carrier protein or a human carrier protein subunit capable of binding somatomedins.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: April 6, 1993
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Emerald M. Spencer, Carol Talkington-Verser
  • Process and installation for continuously fractionating plant, animal or human proteins
    Patent number: 5043427
    Abstract: This invention relates to a process for continuously fractionating plant, animal or human proteins by selective precipitation of the proteins resulting from placing a solution of proteins in contact with a precipitating agent constituted by a fatty acid of 6 to 14 carbon atoms, such as caprylic acid, is characterized in that respective deliveries of fatty acid and of the protein solution are continuously placed in contact in a mixing chamber of small volume with respect to the deliveries, creating a strong stirring in this mixing chamber; the individual deliveries of fatty acid and of protein solution are adjusted to controlled pH and temperature so as to maintain their ratio equal to a predetermined value; the mixture is then allowed to evolve during a phase of maturation so as to form a suspension; this suspension is separated into a liquid part from which are extracted the proteins having remained soluble, and a solid part containing proteins of different nature; and the parameters intervening in the proce
    Type: Grant
    Filed: May 31, 1989
    Date of Patent: August 27, 1991
    Assignee: Foundation Nationale de Transfusion Sanguine
    Inventors: Catherine Leberre, Alain Faure, Gilles Beaudoin, Brigitte Roche, Pierre Colinart, Henri Renon
  • Ion exchange and separation method
    Patent number: 5028696
    Abstract: A method of separating charged molecules having different numbers of charges thereon includes the step of passing the molecules to be separated through ion-exchange material such as an ion-exchange chromatograpy column in normal manner so that molecules to be separated bind to the ion-exchange material. Displacer molecules are then passed through the ion-exchange column to selectively release certain of the molecules to be separated from the ion-exchange material, while others of the molecules to be separated remain bound to the material.
    Type: Grant
    Filed: October 28, 1988
    Date of Patent: July 2, 1991
    Inventors: Anthony R. Torres, Elbert A. Peterson
  • Human cdc25 genes, encoded products and uses thereof
    Patent number: 5441880
    Abstract: Two previously undescribed human cdc25 genes, designated cdc25 A and cdc25 B, which have been shown to have an endogenous tyrosine phosphatase activity that can be specifically activated by B-type cyclin, in the complete absence of cdc2.As a result of the work described herein, new approaches to regulating the cell cycle in eukaryotic cells and, particularly, to regulating the activity of tyrosine specific phosphatases which play a key role in the cell cycle are available. Applicant's invention relates to methods of regulating the cell cycle and, specifically, to regulating activation of cdc2-kinase, through alteration of the activity and/or levels of tyrosine phosphatases, particularly cdc25 phosphatase, and B-type cyclin or through alteration of the interaction of components of MPF, particularly the association of cdc25 with cyclin, cdc2 or the cdc2/cyclin B complex. The present invention also relates to agents or compositions useful in the method of regulating (inhibiting or enhancing) the cell cycle.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: August 15, 1995
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Konstantin Galaktionov
  • Process for the preparation of a high purity protamine-DNA complex and process for use of same
    Patent number: 5187260
    Abstract: A process is disclosed in which high purity protamine-DNA complexes are prepared by collecting nucleoprotamines specific developmental stages of a life form, specifically, amphibian, egg by low temperature processing. The process also includes the steps of sequential homogenization in a high concentration aqueous salt solution at a buffered low pH, followed by ultracentrifugation to remove insoluble matter. Either a crude mixture or pure isolate of the complexes may be produced. Pure isolates require aqueous chloroform extraction to isolate protein and to remove lipids. Lyophilization then removes chloroform and excess water. The isolate is then fractionated by single pass alumina chromatography. Dialysis against pure water removes salts. Repeated lyophilization removes excess water and concentrates single protamines and protamine-like proteins. The mixture may then be reconstituted with 5% weight/volume heterologous or homologous DNA, in order to shield from charge toxicity.
    Type: Grant
    Filed: April 15, 1991
    Date of Patent: February 16, 1993
    Inventors: Sharifa Karali, John K. Barberii
  • Stable, optically clear compositions
    Patent number: 6509044
    Abstract: A process for preparing an aqueous composition for the preparation of optically clear products, especially beverages, having enhanced stability in syrup and bioavailability for human or animal healthcare. The compositions include an oil soluble ingredient and a primary and a secondary surfactant which match the fatty acid profile of the oil soluble ingredient and follow specific ratios of oil soluble ingredient to emulsifier and specific ratios of primary to cosurfactant.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: January 21, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Maarten Van Den Braak, Andrew Symonds, Michael Anthony Ford
  • Remote wire feeder
    Patent number: 7294808
    Abstract: A wire feeder including a motor driving a set of feed rolls to force a welding wire from a spool through a welding torch to a welding operation. The wire feeder has an input lead to be connected to the output lead of one of a plurality of remotely located power sources, each having a signal receiver for receiving transmitted signal with a code unique to one of the power sources. The receiver having an output for controlling a parameter or condition of the one power source in accordance with a received signal with the unique code. A transmitter on each of said plurality of power sources for transmitting on its output lead a coded signal specific to the power source. A signal receiver on said wire feeder to receive a unique code from the specific power source actually connected to the wire feeder and a circuit on the wire feeder for transmitting command signals from the wire feeder, which command signals each have the unique code specific to the power source connected to said wire feeder.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: November 13, 2007
    Assignee: Lincoln Global, Inc.
    Inventors: Edward M. Furman, Keith L. Clark
Narrow Results

Filter by US Classification